REG-4basebio Plc: Lease of Manufacturing Facility

4BasebioAnnouncement

Today 07:00

4basebio PLC

("4basebio" or the "Company")

4basebio announces major expansion to support the growing demand of RUO and HQ
synthetic DNA with lease of an innovation hub and manufacturing facility in
Cambridge, UK

Cambridge, UK, 31 March 2026 –                                              
                                                                              
       4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing
and nucleic acids for next-generation therapeutics, announces a significant
expansion into a new innovation hub and manufacturing facility in Cambridge,
UK, supporting growing demand for research and high-quality grade
manufacturing of synthetic DNA for gene and cell therapies, mRNA vaccines,
genome editing, or DNA vaccines.

31-35 Saxon Way, Bar Hill, is being leased from Peterhouse, the University of
Cambridge’s oldest college, who have a long tradition of supporting academic
excellence and scientific innovation. 4basebio is expected to move into the
facility late summer 2026, once the building has been developed.

The new facility will provide approximately 26,500 square feet of
purpose-built space, including 7,500 square feet of specialised laboratory
space with 15 individual labs equipped with advanced biosafety cabinets, fume
hoods, and state-of-the-art air handling systems, plus cold room and dedicated
IT infrastructure. It will also house modern office space for staff as well as
an additional 7,500 square feet allocated for future expansion, with 2,000
square feet of additional lab space already in the design phase.

The build-out and construction is being delivered by Zero Workspace, a
specialist in the design and delivery of complex laboratory and technical
workspaces for life sciences and innovation-led occupiers across the UK.

Demand for next-generation therapeutics is increasing, driving biotech and
pharmaceutical companies to source high-quality synthetic DNA from trusted
providers. DNA is critical for mRNA vaccines and cell and gene therapies,
particularly as personalised medicine advances. Compared with plasmid DNA,
synthetic DNA offers advantages in purity, safety and scalability. As
development pipelines mature, demand for research and high-quality DNA
manufacturing is expected to grow, and this facility enables 4basebio to meet
that demand.

4basebio would also like to thank Seb Denby, Partner at Creative Places, for
his assistance in our search for new premises including the detailed due
diligence and brokering that secured this new facility.

Dr Amy Walker, Chief                                                          
                                                        Executive Officer of
4basebio, said:                                                               
                                                                              
     "Our customers rely on us to provide high quality synthetic DNA to meet
demand for next generation genomic therapies including RNA therapeutics, cell
and gene therapy, and vaccine development. This new facility strengthens our
ability to support our customers as they advance their drug development
through clinical phases. We're proud to be part of Cambridge's world-class
life sciences ecosystem, and deliver on our commitment to becoming the partner
of choice for our partners"

Barnaby Clark, Director at Zero Workspace, added:                             
                                                                              
                                                    “We’re proud to be
supporting 4basebio on the delivery of this new facility that will allow them
to continue to perform their pioneering work to support the next-generation of
medicine. The project builds on our growing track record in designing and
delivering high-specification laboratory environments, enabling innovative
companies to scale and advance cutting-edge scientific work.”

For further enquiries, please contact:

 4basebio PLC                                      +44 (0)12 2396 7943  
 Dr Amy Walker, CEO                                                     
                                                                        
 Cairn Financial Advisers LLP (Nominated Adviser)  +44 (0)20 7213 0880  
 Jo Turner / Sandy Jamieson / Ed Downes                                 
                                                                        
 Cavendish Capital Markets Limited (Joint Broker)  +44 (0)20 7220 0500  
 Geoff Nash / Nigel Birks                                               
                                                                        
 RBC Capital Markets (Joint Broker)                +44 (0)20 7653 4000  
 Kathryn Deegan / Matthew Coakes                                        
                                                                        
 ICR Healthcare (Media and Investor Relations)     +44 (0)203 707 5700  
 Mary-Jane Elliott / Jessica Hodgson                                    
                                                                        

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the
use of synthetic DNA to enable next-generation therapeutics and vaccines.
Through its proprietary enzymatic DNA synthesis platform, 4basebio produces
GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,
overcoming the limitations of plasmid-based systems. The company offers
application-specific DNA constructs tailored to the diverse needs of gene
therapies, genome editing, mRNA production, and DNA vaccines, helping partners
accelerate proof-of-concept studies and reach clinical milestones more
efficiently while maintaining the highest standards of safety and quality.

For more information, visit                                                   
                                                        4basebio.com          
                                   (https://www.4basebio.com/)                
                                             .



Copyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved